Aytu BioPharma, Inc. (NASDAQ: AYTU) related to its sale to Rosemont Pharmaceuticals Holdings, Inc. Under the terms of the proposed transaction, Aytu shareholders are expected to receive $2.70 in cash per share.
Aytu BioPharma, Inc. (NASDAQ: AYTU) related to its sale to Rosemont Pharmaceuticals Holdings, Inc. Under the terms of the proposed transaction, Aytu shareholders are expected to receive $2.70 in cash per share.